CN116999564A - 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法 - Google Patents

抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法 Download PDF

Info

Publication number
CN116999564A
CN116999564A CN202311004815.2A CN202311004815A CN116999564A CN 116999564 A CN116999564 A CN 116999564A CN 202311004815 A CN202311004815 A CN 202311004815A CN 116999564 A CN116999564 A CN 116999564A
Authority
CN
China
Prior art keywords
cancer
subject
parpi
cell
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311004815.2A
Other languages
English (en)
Chinese (zh)
Inventor
C·A·哈西格
B·W·斯特劳斯
R·J·汉森
K·L·安德雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sierra Oncology Inc
Original Assignee
Sierra Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sierra Oncology Inc filed Critical Sierra Oncology Inc
Publication of CN116999564A publication Critical patent/CN116999564A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202311004815.2A 2017-04-10 2018-04-10 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法 Pending CN116999564A (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201762483888P 2017-04-10 2017-04-10
US62/483,888 2017-04-10
US201762552364P 2017-08-30 2017-08-30
US62/552,364 2017-08-30
US201862614268P 2018-01-05 2018-01-05
US62/614,268 2018-01-05
US201862635394P 2018-02-26 2018-02-26
US62/635,394 2018-02-26
US201862650185P 2018-03-29 2018-03-29
US62/650,185 2018-03-29
PCT/US2018/026917 WO2018191277A1 (en) 2017-04-10 2018-04-10 Chk1 (sra737)/parpi combination methods of inhibiting tumor growth
CN201880024426.7A CN110582490A (zh) 2017-04-10 2018-04-10 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880024426.7A Division CN110582490A (zh) 2017-04-10 2018-04-10 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法

Publications (1)

Publication Number Publication Date
CN116999564A true CN116999564A (zh) 2023-11-07

Family

ID=63793688

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311004815.2A Pending CN116999564A (zh) 2017-04-10 2018-04-10 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法
CN201880024426.7A Pending CN110582490A (zh) 2017-04-10 2018-04-10 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880024426.7A Pending CN110582490A (zh) 2017-04-10 2018-04-10 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法

Country Status (9)

Country Link
US (1) US11596637B2 (enExample)
EP (1) EP3609884A4 (enExample)
JP (1) JP7273791B2 (enExample)
KR (1) KR102645511B1 (enExample)
CN (2) CN116999564A (enExample)
AU (2) AU2018250552B2 (enExample)
CA (1) CA3059576A1 (enExample)
MX (1) MX2019012176A (enExample)
WO (1) WO2018191277A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200157638A1 (en) * 2017-06-01 2020-05-21 Sierra Oncology, Inc. Biomarkers and patient selection strategies
KR20200126388A (ko) * 2018-02-26 2020-11-06 시에라 온코로지, 인코퍼레이티드 Chk1 저해제를 포함하는 암의 치료 방법
CA3135165A1 (en) * 2019-03-28 2020-10-01 Sierra Oncology, Inc. Methods of treating cancer with chk1 inhibitors
CN114072526A (zh) * 2019-05-14 2022-02-18 塞拉肿瘤学公司 使用chk1抑制剂治疗癌症的方法
KR102285996B1 (ko) * 2019-08-08 2021-08-05 차의과학대학교 산학협력단 혈관신생을 억제하는 데 사용하기 위한 조성물 및 그 용도
EP4087561A4 (en) * 2020-01-07 2024-02-14 Shanghai Huayu Biotechnology Co., Ltd. CANCER COMBINATION THERAPY USING A CHK INHIBITOR
EP4196614A4 (en) 2020-08-12 2024-12-18 Boundless Bio, Inc. COMPOSITIONS OF REPLICATION STRESS SIGNAL PATHWAYS AND METHODS FOR TREATING CANCER
KR20230146593A (ko) * 2021-02-16 2023-10-19 리본 테라퓨틱스 인코포레이티드 Parp7 억제제에 대한 투여량 레지멘

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743003A (zh) * 2007-05-25 2010-06-16 阿斯利康(瑞典)有限公司 用于治疗癌症的chk和parp抑制剂的组合
CN104302635A (zh) * 2012-05-15 2015-01-21 癌症研究技术有限公司 5-[[4-[[吗啉-2-基]甲基氨基]-5-(三氟甲基)-2-吡啶基]氨基]吡嗪-2-腈及其治疗应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US20050250836A1 (en) * 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
CA2714003A1 (en) 2008-02-04 2009-08-13 Dana-Farber Cancer Institute, Inc. Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
JP6091422B2 (ja) * 2010-11-16 2017-03-08 アレイ バイオファーマ、インコーポレイテッド チェックポイントキナーゼ１阻害剤とｗｅｅ１キナーゼ阻害剤の組み合わせ
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
GB201316526D0 (en) * 2013-09-17 2013-10-30 King S College London Biomarkers
US10676746B2 (en) 2013-11-22 2020-06-09 Fred Hutchinson Cancer Research Center Methods for identifying therapeutic targets and treating monitoring cancers
WO2018191299A1 (en) 2017-04-10 2018-10-18 Sierra Oncology, Inc. Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
US20200157638A1 (en) 2017-06-01 2020-05-21 Sierra Oncology, Inc. Biomarkers and patient selection strategies
KR20200126388A (ko) 2018-02-26 2020-11-06 시에라 온코로지, 인코퍼레이티드 Chk1 저해제를 포함하는 암의 치료 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743003A (zh) * 2007-05-25 2010-06-16 阿斯利康(瑞典)有限公司 用于治疗癌症的chk和parp抑制剂的组合
CN104302635A (zh) * 2012-05-15 2015-01-21 癌症研究技术有限公司 5-[[4-[[吗啉-2-基]甲基氨基]-5-(三氟甲基)-2-吡啶基]氨基]吡嗪-2-腈及其治疗应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HYOUNG KIM 等: "Targeting theATR/CHK1Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models", 《CLINICAL CANCER RESEARCH》, vol. 23, no. 12, 19 December 2016 (2016-12-19), pages 3097 - 3108 *
YEVGENIY KIM等: "Reverse the Resistance to PARP Inhibitors", 《INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES》, vol. 13, no. 2, 17 February 2017 (2017-02-17), pages 198 - 208 *

Also Published As

Publication number Publication date
EP3609884A1 (en) 2020-02-19
AU2018250552A1 (en) 2019-11-14
JP2020516693A (ja) 2020-06-11
KR20200009004A (ko) 2020-01-29
US11596637B2 (en) 2023-03-07
KR102645511B1 (ko) 2024-03-08
CN110582490A (zh) 2019-12-17
CA3059576A1 (en) 2018-10-18
WO2018191277A1 (en) 2018-10-18
JP7273791B2 (ja) 2023-05-15
MX2019012176A (es) 2020-02-19
US20210077499A1 (en) 2021-03-18
EP3609884A4 (en) 2021-01-06
AU2018250552B2 (en) 2022-08-04
AU2022259818A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
KR102645511B1 (ko) 종양 성장을 저해하는 CHK1(SRA737)/PARPi 조합 방법
Frühwald et al. Atypical teratoid/rhabdoid tumors—current concepts, advances in biology, and potential future therapies
Matutino et al. CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
Richardson et al. Atypical teratoid rhabdoid tumour: from tumours to therapies
WO2018191299A1 (en) Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
Rominiyi et al. DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies
Ganguly et al. Role of biomarkers in the development of PARP inhibitors
WO2021184990A1 (zh) 一种增敏剂药物及药物组合及应用
JP7579781B2 (ja) Ｃｄｃ７阻害剤を含む癌の治療方法
Aung et al. A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma
US20190055563A1 (en) Polymerase q as a target in hr-deficient cancers
JP2024012649A (ja) Ｃｈｋ１阻害剤を含む癌の治療方法
AU2018278336A1 (en) Biomarkers and patient selection strategies
JP2025090749A (ja) Ｃｈｋ１阻害剤を含む、がんを治療するための医薬組成物
WO2025076500A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
Kebir et al. CTNI-79. PRICOTTF TRIAL: A PHASE I/II TRIAL OF TTFIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA
Shakeel et al. Emerging small-molecule inhibitors of ATM kinase targeting cancer therapy
Ashrafi et al. TARGETING HEME AS AN EFFECTIVE STRATEGY TO CONTROL RESISTANT TUMORS
Yao et al. Jatrorrhizine Exhibits an Antitumor Effect Against Gefitinib‐resistant Non‐small Cell Lung Cancer via Inhibiting PI3K/mTOR Phosphorylation
Marquardt Preclinical evaluation of HDAC inhibitors for epigenetic therapy of primary brain tumors
Ison et al. FDA Approval Summary: Niraparib for the maintenance treatment of patients with

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination